

Wearable Injectors Market (7th Edition): Distribution by Type of Device (Patch Pump / On Body Injectors and Wearable Infusion Pump), Usability (Disposable and Reusable), Therapeutic Area (Autoimmune Disorders, Cardiovascular Disorders, Metabolic Disorders, Neurological Disorders, Oncological Disorders and Other Disorders) and Key Geographical Regions (North America, Europe, Asia, Latin America and Middle East and North Africa): Industry Trends and Global Forecasts, 2023-2035

<https://marketpublishers.com/r/WD8F61345346EN.html>

Date: August 2023

Pages: 690

Price: US\$ 4,799.00 (Single User License)

ID: WD8F61345346EN

Abstracts

The global wearable injectors market is expected to reach USD 4.3 billion in 2023 anticipated to grow at a CAGR of 9% during the forecast period 2023-2035.

The increasing global population has led to a rise in chronic illnesses like diabetes, autoimmune disorders, heart problems, and cancer. To address this challenge, the pharmaceutical industry is taking significant steps, using innovative strategies and focusing on patients' needs. Current treatments mostly involve giving medications orally or through injections, with injections being more common. However, injecting drugs can be inconvenient for patients due to frequent dosing, potential errors, contamination risks, and needle injuries, impacting how well they stick to their treatment plan and affecting its effectiveness.

Luckily, there have been remarkable advancements in drug delivery devices, particularly wearable ones like on-body injectors. These devices offer sustained effects

and improve how well patients follow their treatment. Larger wearable injectors, especially, have simplified the process and boosted adherence by offering various dosing options like continuous delivery. They also come with safety features that reduce needle injuries, making them preferable for at-home treatments.

The popularity of these devices has encouraged pharmaceutical and medical device companies to add more features to their products, such as AI algorithms, mobile apps for health monitoring, reminder systems, and signals confirming drug delivery. With ongoing innovations, the use of wearable injectors is expected to increase significantly, driving market growth in the coming years.

Report Coverage

The report conducts an examination of the wearable injectors market, categorizing it by type of device, usability, therapeutic area and key geographical regions

Analysis is performed on various factors such as drivers, limitations, opportunities, and challenges affecting market growth.

An evaluation is made regarding the potential advantages and obstacles within the market, offering insights into the competitive landscape for key players.

Revenue forecasting is provided for market segments concerning six major regions.

Detailed clarification of research methodologies is presented, encompassing assumptions, quality control measures, and systematic approaches employed to ensure accurate findings in the study of the wearable injectors market.

Analysis of historical trends and economic influencers, including currency fluctuations, foreign exchange impacts, recessions, and inflation measurements, that affect the overall market for large volume wearable injectors.

A concise overview is presented, highlighting the current status of wearable injectors, anticipated short to long-term evolution, and key findings from the research.

An overview is provided of traditional parenteral drug delivery devices,

emphasizing the factors driving their evolution, importance in enhancing medication adherence, regulatory considerations, and future perspectives.

Detailed evaluations are conducted based on multiple parameters for non-insulin drug delivery, encompassing device status, type, usability, dosage, container, administration route, technology, connectivity, and company landscape.

A comprehensive assessment is made of device-drug combinations, considering development status, device types, usability, drug container, administration route, technology, and company landscape for non-insulin drug delivery.

In-depth evaluations cover various parameters for insulin wearable injectors, including device types, usability, dosage, container volume, diabetes types, control features, connectivity, and the landscape of companies manufacturing these injectors.

Comparative assessments are made of wearable injectors based on company strengths, product competitiveness factors, and manufacturer size.

Detailed profiles are provided, featuring company overviews, financial insights (if available), product portfolios, recent developments, and future outlooks.

Comprehensive profiles detail drug specifications, mechanisms, development status, dosage frequencies, and sales information where available.

A detailed review is conducted of partnerships between stakeholders in the wearable injectors market from 2015 to 2023, considering partnership types, involved players, and geographical implications.

Examination of historical acquisition activities in the industry since 2000 is performed to identify potential acquisition targets for stakeholders.

Review of patents filed/granted related to wearable injectors is conducted, analyzing parameters like patent types, publication year, jurisdiction, player types, emerging focus areas, and leading patents.

Insights into marketed and pipeline drugs/therapies expected to combine with wearable injectors are provided based on drug types, development phases, indications, dosing frequencies, therapy types, and administration routes.

Comprehensive analysis is conducted of completed, ongoing, and planned clinical trials related to wearable injectors, focusing on recruitment status, phases, sponsors, focus areas, therapeutic areas, and geographical locations.

Review of funding instances in wearable injector companies from 2014 to 2023 is provided, including analysis by funding types, diseases targeted, active players, leading investors, and geographical considerations.

Case study discussions are conducted on the involvement of CMOs in manufacturing wearable injectors, detailing their roles in producing various device components and their impact on the supply chain.

In-depth exploration is made of regulatory standards for medical device approvals in major regions, along with a comparative analysis of regulatory and reimbursement landscapes across key global geographies.

Analysis is conducted on growth factors, potential restraints, emerging opportunities, and existing challenges impacting the large volume wearable injectors market.

Discussion is held on future opportunities for wearable injectors, highlighting trends and parameters likely to influence the market's future within a detailed SWOT framework.

Key Market Companies

CCBio

CeQur

Debiotech

E3D Elcam Drug Delivery Devices

Eli Lilly

Enable Injections

Gerresheimer

Insulet

Medtronic

Medtrum Technologies

Pharmasense

Roche

Sonceboz

Weibel CDS

West Pharmaceuticals

SOOIL Development

Contents

1. PREFACE

- 1.1. Large Volume Wearable Injectors Market Overview
- 1.2. Key Market Insights
- 1.3. Scope of the Report
- 1.4. Research Methodology
- 1.5. Frequently Asked Questions
- 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

- 2.1. Chapter Overview
- 2.2. Research Assumptions
- 2.3. Project Methodology
- 2.4. Forecast Methodology
- 2.5. Robust Quality Control
- 2.6. Key Market Segmentations
- 2.7. Key Considerations
 - 2.7.1. Demographics
 - 2.7.2. Economic Factors
 - 2.7.3. Government Regulations
 - 2.7.4. Supply Chain
 - 2.7.5. COVID Impact / Related Factors
 - 2.7.6. Market Access
 - 2.7.7. Healthcare Policies
 - 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

- 3.1. Chapter Overview
- 3.2. Market Dynamics
 - 3.2.1. Time Period
 - 3.2.1.1. Historical Trends
 - 3.2.1.2. Current and Forecasted Estimates
 - 3.2.2. Currency Coverage
 - 3.2.2.1. Overview of Major Currencies Affecting the Market
 - 3.2.2.2. Impact of Currency Fluctuations on the Industry

3.2.3. Foreign Exchange Impact

3.2.3.1. Evaluation of Foreign Exchange Rates and their Impact on Market

3.2.3.2. Strategies for Mitigating Foreign Exchange Risk

3.2.4. Recession

3.2.4.1. Historical Trends Analysis of Past Recessions and Lessons Learnt

3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation

3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy

3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

5.1. Chapter Overview

5.2. Introduction to Drug Delivery Devices

5.3. Conventional Parenteral Drug Delivery Devices

5.3.1. Needlestick Injuries

5.3.2. Incidence and Cost Burden

5.3.3. Prevention of Needlestick Injuries

5.3.4. Government Legislations for the Prevention of Needlestick Injuries

5.4. Emergence of Self-Administration Devices

5.4.1. Key Driving Factors

5.4.1.1. Rising Burden of Chronic Diseases

5.4.1.2. Healthcare Cost Savings

5.4.1.3. Need for Immediate Treatment in Emergency Situations

5.4.1.4. Growing Injectable Drugs Market

5.4.1.5. Need for Improving Medication Adherence

5.5. Available Self-Injection Devices

5.5.1. Prefilled Syringes

5.5.2. Pen-Injectors

5.5.3. Needle-Free Injectors

5.5.4. Autoinjectors

5.5.5. Large Volume Wearable Injectors

5.6. Regulatory Considerations

5.6.1. Medical Devices

5.6.2. Drug Device Combination Products

5.7. Future Perspectives

6. LARGE VOLUME WEARABLE INJECTORS FOR NON-INSULIN DRUGS: CURRENT MARKET LANDSCAPE

6.1. Chapter Overview

6.2. Large Volume Wearable Injectors: Overall Market Landscape

6.3. Large Volume Wearable Injectors for Non-Insulin Drugs: Overall Market Landscape

6.3.1. Analysis by Status of Development

6.3.2. Analysis by Type of Device

6.3.3. Analysis by Usability

6.3.4. Analysis by Type of Dose

6.3.5. Analysis by Type of Drug Container

6.3.6. Analysis by Mode of Drug Filling

6.3.7. Analysis by Container Volume (mL)

6.3.8. Analysis by Route of Administration

6.3.9. Analysis by Mode of Injection

6.3.10. Analysis by Mechanism of Action / Driving Force

6.3.11. Analysis by Type of Technology

6.3.12. Analysis by Availability of Connectivity Feature

6.3.13. Analysis by Type of Compatible Drug

6.3.14. Analysis by Compatibility with High Viscosity Drugs

6.3.15. Analysis by Therapeutic Area

6.4. Large Volume Wearable Injectors for Non-Insulin Drugs: Developer Landscape

6.4.1. Analysis by Year of Establishment

6.4.2. Analysis by Company Size

6.4.3. Analysis by Location of Headquarters

6.3.4. Leading Players: Analysis by Number of Large Volume Wearable Injectors Manufactured for Non-Insulin Drugs

7. LARGE VOLUME DRUG DEVICE COMBINATIONS FOR NON-INSULIN DRUGS: CURRENT MARKET LANDSCAPE

7.1. Chapter Overview

7.2. Large Volume Drug Device Combinations for Non-Insulin Drugs: Overall Market Landscape

7.2.1. Analysis by Status of Development

7.2.2. Analysis by Type of Device

7.2.3. Analysis by Usability

7.2.4. Analysis by Type of Dose

- 7.2.5. Analysis by Type of Drug Container
- 7.2.6. Analysis by Mode of Drug Filling
- 7.2.7. Analysis by Container Volume (mL)
- 7.2.8. Analysis by Route of Administration
- 7.2.9. Analysis by Mode of Injection
- 7.2.10. Analysis by Type of Compatible Drug
- 7.2.11. Analysis by Mechanism of Action / Driving Force
- 7.2.12. Analysis by Type of Technology
- 7.2.13. Analysis by Therapeutic Area

7.3 Large Volume Drug Device Combinations for Non-Insulin Drugs: Developer Landscape

- 7.3.1. Analysis by Year of Establishment
- 7.3.2. Analysis by Company Size
- 7.3.3. Analysis by Location of Headquarters
- 7.3.4. Leading Players: Analysis by Number of Drug Device Combinations for Non-Insulin Drugs

8. LARGE VOLUME WEARABLE INJECTORS FOR INSULIN DRUGS: CURRENT MARKET LANDSCAPE

8.1. Chapter Overview

8.2. Large Volume Wearable Injectors for Insulin Drugs: Overall Market Landscape

- 8.2.1. Analysis by Status of Development
- 8.2.2. Analysis by Type of Device
- 8.2.3. Analysis by Usability
- 8.2.4. Analysis by Type of Dose
- 8.2.5. Analysis by Mode of Drug Filling
- 8.2.6. Analysis by Container Volume (mL)
- 8.2.7. Analysis by Type of Diabetes
- 8.2.8. Analysis by Type of Combination Insulin
- 8.2.9. Analysis by Period of Use (Days)
- 8.2.10. Analysis by Type of Device Control Feature
- 8.2.11. Analysis by Availability of Interoperable Device
- 8.2.12. Analysis by Availability of Continuous Glucose Monitoring (CGM) / Blood Glucose Meters (BGM) System
- 8.2.13. Analysis by Availability of Automatic Insulin Delivery (AID) / Artificial Pancreas
- 8.2.14. Analysis by Type of Automated Insulin Delivery (AID) Feature
- 8.2.15. Analysis by Availability of Connectivity Feature
- 8.2.16. Analysis by Waterproof Capabilities

- 8.3. Large Volume Wearable Injectors for Insulin Drugs: Developer Landscape
 - 8.3.1. Analysis by Year of Establishment
 - 8.3.2. Analysis by Company Size
 - 8.3.3. Analysis by Location of Headquarters
 - 8.3.4. Leading Players: Analysis by Number of Large Volume Wearable Injectors Manufactured for Insulin Drugs

9. PRODUCT COMPETITIVENESS ANALYSIS

- 9.1. Chapter Overview
- 9.2. Assumptions / Key Parameters
- 9.3. Methodology
- 9.4. Product Competitiveness Analysis: Large Volume Wearable Injectors for Non-Insulin Drugs
 - 9.4.1. Products Developed by Players in North America
 - 9.4.2. Products Developed by Players in Europe
 - 9.4.3. Products Developed by Players in Asia and Middle East and North Africa
- 9.5. Product Competitiveness Analysis: Large Volume Drug Device Combinations for Non-Insulin Drugs
 - 9.5.1. Products Developed by Players in North America
 - 9.5.2. Products Developed by Players in Europe
 - 9.5.3. Products Developed by Players in Middle East and North Africa
- 9.6. Product Competitiveness Analysis: Large Volume Wearable Injectors for Insulin Drugs
 - 9.6.1. Products Developed by Players in North America
 - 9.6.2. Products Developed by Players in Europe
 - 9.6.3. Products Developed by Players in Asia and Middle East and North Africa

10. LARGE VOLUME WEARABLE INJECTOR DEVELOPERS: COMPANY PROFILES

- 10.1. Chapter Overview
- 10.2. Key Players Developing Large Volume Wearable Injectors for Non-Insulin Drugs
 - 10.2.1. CCBio
 - 10.2.1.1. Company Overview
 - 10.2.1.2. Product Portfolio
 - 10.2.1.3. Recent Developments and Future Outlook
 - 10.2.2. E3D Elcam Drug Delivery Devices
 - 10.2.2.1. Company Overview

- 10.2.2.2. Product Portfolio
- 10.2.2.3. Recent Developments and Future Outlook
- 10.2.3. Enable Injections
 - 10.2.3.1. Company Overview
 - 10.2.3.2. Product Portfolio
 - 10.2.3.3. Recent Developments and Future Outlook
- 10.2.4. Gerresheimer
 - 10.2.4.1. Company Overview
 - 10.2.4.2. Financial Information
 - 10.2.4.3. Product Portfolio
 - 10.2.4.4. Recent Developments and Future Outlook
- 10.2.5. Sonceboz
 - 10.2.5.1. Company Overview
 - 10.2.5.2. Product Portfolio
 - 10.2.5.3. Recent Developments and Future Outlook
- 10.2.6. Weibel CDS
 - 10.2.6.1. Company Overview
 - 10.2.6.2. Product Portfolio
 - 10.2.6.3. Recent Developments and Future Outlook
- 10.2.7. West Pharmaceuticals
 - 10.2.7.1. Company Overview
 - 10.2.4.2. Financial Information
 - 10.2.7.3. Product Portfolio
 - 10.2.7.4. Recent Developments and Future Outlook
- 10.3. Key Players Developing Large Volume Wearable Injectors for Insulin Drugs
 - 10.3.1. CeQur
 - 10.3.1.1. Company Overview
 - 10.3.1.2. Product Portfolio
 - 10.3.1.3. Recent Developments and Future Outlook
 - 10.3.2. Debiotech
 - 10.3.2.1. Company Overview
 - 10.3.2.2. Product Portfolio
 - 10.3.2.3. Recent Developments and Future Outlook
 - 10.3.3. Eli Lilly
 - 10.3.3.1. Company Overview
 - 10.3.3.2. Financial Information
 - 10.3.3.3. Product Portfolio
 - 10.3.3.4. Recent Developments and Future Outlook
 - 10.3.4. Insulet

- 10.3.4.1. Company Overview
- 10.3.4.2. Financial Information
- 10.3.4.3. Product Portfolio
- 10.3.4.4. Recent Developments and Future Outlook
- 10.3.5. Medtronic
 - 10.3.5.1. Company Overview
 - 10.3.5.2. Financial Information
 - 10.3.5.3. Product Portfolio
 - 10.3.5.4. Recent Developments and Future Outlook
- 10.3.6. Medtrum Technology
 - 10.3.6.1. Company Overview
 - 10.3.6.2. Product Portfolio
 - 10.3.6.3. Recent Developments and Future Outlook
- 10.3.7. PharmaSens
 - 10.3.7.1. Company Overview
 - 10.3.7.2. Product Portfolio
 - 10.3.7.3. Recent Developments and Future Outlook
- 10.3.8. Roche
 - 10.3.8.1. Company Overview
 - 10.3.8.2. Financial Information
 - 10.3.8.3. Product Portfolio
 - 10.3.8.4. Recent Developments and Future Outlook
- 10.3.9. SOOIL Development
 - 10.3.9.1. Company Snapshot
 - 10.3.9.2. Product Portfolio
 - 10.3.9.3. Recent Developments and Future Outlook

11. DRUG-DEVICE COMBINATIONS: DEVICE PROFILES

- 11.1. Chapter Overview
- 11.2. 3 mL Micropump (Furosemide)
- 11.3. 3M hMTS (Adalimumab)
- 11.4. D-mine Pump (Apomorphine)
- 11.5. FUROSCIX® On-body Infusor (Furosemide)
- 11.6. Herceptin sc Injection (Herceptin)
- 11.7. ND0612H Belt Pump (Levodopa / Carbidopa)
- 11.8. ND0612L Belt Pump (Levodopa / Carbidopa)
- 11.9. ND0612L Next Generation Patch Pump (Levodopa / Carbidopa)
- 11.10. ND0701 (Apomorphine)

- 11.11. ND0901 (Levodopa / Carbidopa)
- 11.12. Neulasta OnPro On-Body Injector (Neulasta or Pegfilgrastim)
- 11.13. Pushtronex System (Repatha or Evolocumab)
- 11.14. SMT-201(Ketorolac)
- 11.15. SMT-301 (Bupivacaine)
- 11.16. The LUTREPULSE System (Lutrepulse)
- 11.17. Trevyent (Treprostinil)
- 11.18. ULTOMRIS Smart Dose Injector (Ravulizumab)

12. PARTNERSHIPS AND COLLABORATIONS

- 12.1. Chapter Overview
- 12.2. Partnership Models
- 12.3. Large Volume Wearable Injectors: Partnerships and Collaborations
 - 12.3.1. Analysis by Year of Partnership
 - 12.3.2. Analysis by Type of Partnership
 - 12.3.3. Analysis by Year and Type of Partnership
 - 12.3.4. Analysis by Type of Partner
 - 12.3.5. Analysis by Year of Partnership and Type of Partner
 - 12.3.6. Analysis by Type of Device
 - 12.3.7. Most Active Players: Analysis by Number of Partnerships
 - 12.3.8. Most Active Players: Analysis by Type of Partnership
 - 12.3.9. Analysis by Geography
 - 12.3.9.1. Local and International Agreements
 - 12.3.9.2. Intercontinental and Intracontinental Agreements

13. KEY ACQUISITION TARGETS

- 13.1. Chapter Overview
- 13.2. Scope and Methodology
- 13.3. Scoring Criteria and Key Assumptions
- 13.4. Potential Acquisition Targets: Non-Insulin Drug Delivery Device Developers
- 13.5. Potential Acquisition Targets: Insulin Drug Delivery Device Developers
- 13.6. Concluding Remarks

14. PATENT ANALYSIS

- 14.1. Chapter Overview
- 14.2. Scope and Methodology

- 14.3. Large Volume Wearable Injectors: Patent Analysis
 - 14.3.1. Analysis by Type of Patent
 - 14.3.2. Analysis by Patent Publication Year
 - 14.3.3. Analysis by Jurisdiction
 - 14.3.4. Analysis by CPC Symbols
 - 14.3.5. Word Cloud: Emerging Focus Areas
 - 14.3.6. Analysis by Type of Organization
 - 14.3.7 Most Active Players: Analysis by Number of Patents
- 14.4. Large Volume Wearable Injectors: Patent Benchmarking Analysis
 - 14.4.1. Analysis by Patent Characteristics
- 14.5. Large Volume Wearable Injectors: Patent Valuation Analysis

15. LARGE VOLUME WEARABLE INJECTORS: LIKELY DRUG CANDIDATES

- 15.1. Chapter Overview
- 15.2. Marketed Drugs
 - 15.2.1. Most Likely Candidates for Delivery via Large Volume Wearable Injectors
 - 15.2.2. Likely Candidates for Delivery via Large Volume Wearable Injectors
 - 15.2.3. Less Likely Candidates for Delivery via Large Volume Wearable Injectors
 - 15.2.4. Least Likely Candidates for Delivery via Large Volume Wearable Injectors
- 15.3. Clinical stage Drugs
 - 15.3.1.1. Most Likely Candidates for Delivery via Large Volume Wearable Injectors
 - 15.3.1.2. Likely Candidates for Delivery via Large Volume Wearable Injectors
 - 15.3.1.3. Less Likely Candidates for Delivery via Large Volume Wearable Injectors
 - 15.3.1.4. Least Likely Candidates for Delivery via Large Volume Wearable Injectors

16. CLINICAL TRIAL ANALYSIS

- 16.1. Chapter Overview
- 16.2. Scope and Methodology
- 16.3. Large Volume Wearable Injectors: Clinical Trial Analysis
 - 16.3.1. Analysis by Trial Recruitment Status
 - 16.3.2. Analysis by Trial Registration Year
 - 16.3.3 Analysis of Enrolled Patent Population by Trial Registration Year
 - 16.3.4. Analysis by Trial Phase
 - 16.3.5. Analysis of Enrolled Patient Population by Trial Phase
 - 16.3.6. Analysis by Trial Registration Year and Trial Recruitment Status
 - 16.3.7. Analysis by Study Design
 - 16.3.8. Analysis by Type of Sponsor / Collaborator

- 16.3.9. Leading Players: Analysis by Number of Registered Trials
- 16.3.10. Word Cloud: Key Focus Areas
- 16.3.11. Analysis by Therapeutic Area
- 16.3.12. Most Popular Large Volume Wearable Injectors: Analysis by Number of Registered Trials
- 16.3.13. Analysis by Geography
- 16.3.14. Analysis by Trial Recruitment Status and Geography
- 16.3.15. Analysis of Enrolled Patient Population by Trial Recruitment Status and Geography

17. FUNDING AND INVESTMENT ANALYSIS

- 17.1. Chapter Overview
- 17.2. Types of Funding
- 17.3. Large Volume Wearable Injectors: Funding and Investment Analysis
 - 17.3.1. Analysis by Year of Funding
 - 17.3.2. Analysis of Amount Invested by Year
 - 17.3.3. Analysis by Type of Funding
 - 17.3.4. Analysis by Type of Device
 - 17.3.5. Analysis of Amount Invested by Year and Type of Funding
 - 17.3.6. Analysis of Amount Invested by Type of Device
 - 17.3.7. Analysis by Target Disease Indication
 - 17.3.8. Most Active Players: Analysis by Number of Funding Instances
 - 17.3.9. Most Active Players: Analysis by Amount Invested
 - 17.3.10. Leading Investors: Analysis by Number of Funding Instances
 - 17.3.11. Analysis by Geography

18. CASE STUDY: ROLE OF CONTRACT MANUFACTURING ORGANIZATIONS IN DEVICE DEVELOPMENT SUPPLY CHAIN

- 18.1. Chapter Overview
- 18.2. Device Development Supply Chain
- 18.3. Role of Contract Manufacturing Organizations (CMOs) in Device Development
- 18.4. List of CMOs
 - 18.4.1. Geographical Distribution of CMOs
- 18.5 Medical Devices Design and Development Service Providers

19. REGULATORY AND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES

- 19.1. Chapter Overview
- 19.2. General Regulatory and Reimbursement Guidelines for Medical Devices
- 19.3. Regulatory and Reimbursement Landscape in North America
 - 19.3.1. The US Scenario
 - 19.3.1.1. Regulatory Authority
 - 19.3.1.2. Review / Approval Process
 - 19.3.1.3. Reimbursement Landscape
 - 19.3.1.3.1. Payer Mix
 - 19.3.1.3.2. Reimbursement Process
 - 19.3.2. The Canadian Scenario
 - 19.3.2.1. Regulatory Authority
 - 19.3.2.2. Review / Approval Process
 - 19.3.2.3. Reimbursement Landscape
 - 19.3.2.3.1. Payer Mix
 - 19.3.2.3.2. Reimbursement Process
 - 19.3.3. The Mexican Scenario
 - 19.3.3.1. Regulatory Authority
 - 19.3.3.2. Review / Approval Process
 - 19.3.3.3. Reimbursement Landscape
 - 19.3.3.3.1. Payer Mix
- 19.4. Regulatory and Reimbursement Landscape in Europe
 - 19.4.1. Overall Scenario
 - 19.4.1.1. Overall Regulatory Authority
 - 19.4.1.2. Overall Review / Approval Process
 - 19.4.2. The UK Scenario
 - 19.4.2.1. Regulatory Authority
 - 19.4.2.2. Review / Approval Process
 - 19.4.2.3. Reimbursement Landscape
 - 19.4.2.3.1. Payer Mix
 - 19.4.2.3.2. Reimbursement Process
 - 19.4.3. The French Scenario
 - 19.4.3.1. Regulatory Authority
 - 19.4.3.2. Review / Approval Process
 - 19.4.3.3. Reimbursement Landscape
 - 19.4.3.3.1. Payer Mix
 - 19.4.3.3.2. Reimbursement Process
 - 19.4.4. The German Scenario
 - 19.4.4.1. Regulatory Authority
 - 19.4.4.2. Review / Approval Process

- 19.4.4.3. Reimbursement Landscape
 - 19.4.4.3.1. Payer Mix
 - 19.4.4.3.2. Reimbursement Process
- 19.4.5. The Italian Scenario
 - 19.4.5.1. Regulatory Authority
 - 19.4.5.2. Review / Approval Process
 - 19.4.5.3. Reimbursement Landscape
 - 19.4.5.3.1. Payer Mix
 - 19.4.5.3.2. Reimbursement Process
- 19.4.6. The Spanish Scenario
 - 19.4.6.1. Regulatory Authority
 - 19.4.6.2. Review / Approval Process
 - 19.4.6.3. Reimbursement Landscape
 - 19.4.6.3.1. Payer Mix
 - 19.4.6.3.2. Reimbursement Process
- 19.5. Regulatory and Reimbursement Landscape in Asia-Pacific and Rest of the World
 - 19.5.1. The Australian Scenario
 - 19.5.1.1. Regulatory Authority
 - 19.5.1.2. Review / Approval Process
 - 19.5.1.3. Reimbursement Landscape
 - 19.5.1.3.1. Payer Mix
 - 19.5.1.3.2. Reimbursement Process
 - 19.5.2. The Brazilian Scenario
 - 19.5.2.1. Regulatory Authority
 - 19.5.2.2. Review / Approval Process
 - 19.5.2.3. Reimbursement Landscape
 - 19.5.2.3.1. Payer Mix
 - 19.5.2.3.2. Reimbursement Process
 - 19.5.3. The Chinese Scenario
 - 19.5.3.1. Regulatory Authority
 - 19.5.3.2. Review / Approval Process
 - 19.5.3.3. Reimbursement Landscape
 - 19.5.3.3.1. Payer Mix
 - 19.5.3.3.2. Reimbursement Process
 - 19.5.4. The Indian Scenario
 - 19.5.4.1. Regulatory Authority
 - 19.5.4.2. Review / Approval Process
 - 19.5.4.3. Reimbursement Landscape
 - 19.5.4.3.1. Payer Mix

- 19.5.5. The Israeli Scenario
 - 19.5.5.1. Regulatory Authority
 - 19.5.5.2. Review / Approval Process
 - 19.5.5.3. Reimbursement Landscape
 - 19.5.5.3.1. Payer Mix
- 19.5.6. The Japanese Scenario
 - 19.5.6.1. Regulatory Authority
 - 19.5.6.2. Review / Approval Process
 - 19.5.6.3. Reimbursement Landscape
 - 19.5.6.3.1. Payer Mix
 - 19.5.6.3.2. Reimbursement Process
- 19.5.7. The New Zealand Scenario
 - 19.5.7.1. Regulatory Authority
 - 19.5.7.2. Review / Approval Process
 - 19.5.7.3. Reimbursement Landscape
 - 19.5.7.3.1. Payer Mix
 - 19.5.7.3.2. Reimbursement Process
- 19.5.8. The Singaporean Scenario
 - 19.5.8.1. Regulatory Authority
 - 19.5.8.2. Review / Approval Process
 - 19.5.8.3. Reimbursement Landscape
 - 19.5.8.3.1. Payer Mix
 - 19.5.8.3.2. Reimbursement Process
- 19.5.9. The South Korean Scenario
 - 19.5.9.1. Regulatory Authority
 - 19.5.9.2. Review / Approval Process
 - 19.5.9.3. Reimbursement Landscape
 - 19.5.9.3.1. Payer Mix
 - 19.5.9.3.2. Reimbursement Process
- 19.5.10. The South African Scenario
 - 19.5.10.1. Regulatory Authority
 - 19.5.10.2. Review / Approval Process
 - 19.5.10.3. Reimbursement Landscape
- 19.5.11. The Taiwanese Scenario
 - 19.5.11.1. Regulatory Authority
 - 19.5.11.2. Review / Approval Process
 - 19.5.11.3. Reimbursement Landscape
 - 19.5.11.3.1. Payer Mix
 - 19.5.11.3.2. Reimbursement Process

- 19.5.12. The Thailand Scenario
 - 19.5.12.1. Regulatory Authority
 - 19.5.12.2. Review / Approval Process
 - 19.5.12.3. Reimbursement Landscape
- 19.6. Comparison of Regional Regulatory Environment
- 19.7. Concluding Remarks

20. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

- 20.1. Chapter Overview
- 20.2. Market Drivers
- 20.3. Market Restraints
- 20.4. Market Opportunities
- 20.5. Market Challenges
- 20.6. Conclusion

21. MARKET SIZING AND OPPORTUNITY ANALYSIS FOR LARGE VOLUME WEARABLE INJECTORS FOR NON-INSULIN DRUGS

- 21.1. Chapter Overview
- 21.2. Key Assumptions and Methodology
- 21.3. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Estimates (2023-2035) (By Value)
 - 21.3.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2035 (By Value)
 - 21.3.1.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
 - 21.3.1.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
 - 21.3.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2035 (By Value)
 - 21.3.2.1. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
 - 21.3.2.2. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2035 (By Value)

21.3.3.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.3.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.3.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.3.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.3.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Geography, 2035 (By Value)

21.3.4.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.1.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.1.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.1.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.1.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.1.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.1.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in North America, Historical Trends (2017-2022)

and Forecasted Estimates (2023-2035) (By Value)

21.3.4.1.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.1.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.1.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.2.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.2.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.2.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.2.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.2.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.2.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.2.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.2.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.2.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.3.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.3.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.3.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.3.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.3.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.3.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.3.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.3.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.3.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.4.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.4.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.4.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin

Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.4.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.4.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.4.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.4.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.4.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.4.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.4.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.4.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.4.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.4.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.4.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.4.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs

Targeting Cardiovascular Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.4.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs

Targeting Autoimmune Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.4.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs

Targeting Neurological Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.3.4.4.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs

Targeting Other Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)

21.4. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)

21.4.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2035 (By Volume)

21.4.1.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)

21.4.1.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)

21.4.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2035 (By Volume)

21.4.2.1. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)

21.4.2.2. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)

21.4.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2035 (By Volume)

21.4.3.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)

21.4.3.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)

21.4.3.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)

21.4.3.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)

21.4.3.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)

21.4.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distr

I would like to order

Product name: Wearable Injectors Market (7th Edition): Distribution by Type of Device (Patch Pump / On Body Injectors and Wearable Infusion Pump), Usability (Disposable and Reusable), Therapeutic Area (Autoimmune Disorders, Cardiovascular Disorders, Metabolic Disorders, Neurological Disorders, Oncological Disorders and Other Disorders) and Key Geographical Regions (North America, Europe, Asia, Latin America and Middle East and North Africa): Industry Trends and Global Forecasts, 2023-2035

Product link: <https://marketpublishers.com/r/WD8F61345346EN.html>

Price: US\$ 4,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/WD8F61345346EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970